In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Glucagon-like peptide-1 (GLP-1) receptor agonist'
Please login to view adverse reactions.
Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)
- Negative findings
- (2024): Anthony MS+, Diabetes Care 47(4), 712-719 ('anaphylaxis is rare with GLP-1 receptor agonists')
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2024): Salazar CE+, Arch Dermatol Res 316(6), 248 [REVIEW]
- (2024): Ashraf MT+, Am J Ther 31(4), e483-e486 [REVIEW]
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- Negative findings
- (2025): Tanashat M+, Am J Cardiovasc Drugs Apr, Online ahead of print [REVIEW]
- (2024): Jiao BL+, Eur Rev Med Pharmacol Sci 28(8), 3073-3084 [REVIEW]
- (2024): Kornelius E+, Sci Rep 14(1), 24433 (association)
- Negative findings
- (2024): Kerem L+, JAMA Pediatr Oct, Online ahead of print
("a favorable psychiatric safety profile of GLP-1 receptor agonists in adolescents") - (2024): Ruggiero R+, Pharmaceuticals (Basel) 17(2), 147 [REVIEW] ("causality requires further investigation") (pharmacovigilance / pharmacoepidemiology)
- (2024): Forouzanmehr B+, Naunyn Schmiedebergs Arch Pharmacol Aug, Online ahead of print [REVIEW] (association)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
- (2016): Janzen KM+, Ann Pharmacother 50(8), 656 [REVIEW]
- (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]
Dyspepsia / functional dyspepsia (indigestion) (see also gastroparesis)
- (2024): Jiao BL+, Eur Rev Med Pharmacol Sci 28(8), 3073-3084 [REVIEW]
Gastrointestinal adverse reaction
- (2025): Douros JD+, Front Endocrinol (Lausanne) Feb (e-Collection) [REVIEW]
- (2025): Guo H+, Obes Pillars Jan (e-Collection) [REVIEW]
- (2025): Sedenho-Prado LG+, Int J Obes (Lond) Apr, Online ahead of print [REVIEW]
- (2025): Tanashat M+, Am J Cardiovasc Drugs Apr, Online ahead of print [REVIEW]
- (2024): Bak M+, Acta Psychiatr Scand Jul, Online ahead of print [REVIEW]
- (2024): Zhou J+, Br J Clin Pharmacol Dec, Online ahead of print ("Glucagon-like peptide-1 receptor agonists are not recommended for use during pregnancy") (pharmacovigilance / pharmacoepidemiology)
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
- (2021): Ryan PM+, J Pediatr May, Online ahead of print [REVIEW]
- (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]
- (2016): Janzen KM+, Ann Pharmacother 50(8), 656 [REVIEW]
Pancreatitis / acute pancreatitis
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
- (2014): Soldevila B+, Med Clin (Barc) (Spanish) 143 Suppl 2, 35 [REVIEW]
- (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]
Otolaryngological adverse effects / otorhinolaryngological adverse effects
- (2025): Pak KY+, Otol Neurotol 46(1), 19-22 (pharmacovigilance / pharmacoepidemiology)
Nephrolithiasis (kidney stones / renal calculi)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
Adverse effects / adverse reactions
- (2025): McCall KL+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2024): Huang YN+, Diabetes Obes Metab Aug, Online ahead of print
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
- Negative findings
- (2024): Balshi A+, Mult Scler Relat Disord Dec, Online ahead of print
- (2024): Zhou J+, Br J Clin Pharmacol Dec, Online ahead of print (association) ("Glucagon-like peptide-1 receptor agonists are not recommended for use during pregnancy") (pharmacovigilance / pharmacoepidemiology)
- Negative findings
- (2024): Dao K+, BMJ Open 14(4), e083550 (no increased risk of pregnancy losses seen in the GLP-1 receptor agonist-exposed group versus a diabetes group and an overweight/obese reference group)
- (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
- (2014): Soldevila B+, Med Clin (Barc) (Spanish) 143 Suppl 2, 35 [REVIEW]
